Artificial intelligence-based model for the recurrence of hepatocellular carcinoma after liver transplantation

被引:2
|
作者
Altaf, Abdullah [1 ,2 ]
Mustafa, Ahmed [3 ]
Dar, Abdullah [2 ]
Nazer, Rashid [4 ]
Riyaz, Shahzad [5 ]
Rana, Atif [4 ]
Bhatti, Abu Bakar Hafeez [2 ,6 ]
机构
[1] King Edward Med Univ, Lahore, Pakistan
[2] Shifa Int Hosp, Dept HPB & Liver Transplant Surg, Sector H-8-4,Pitras Bukhari Rd, Islamabad 44000, Pakistan
[3] Natl Univ Sci & Technol, Dept Robot & Artificial Intelligence, Islamabad, Pakistan
[4] Shifa Int Hosp, Dept Radiol, Islamabad, Pakistan
[5] Shifa Int Hosp, Dept Gastroenterol & Hepatol, Islamabad, Pakistan
[6] Shifa Tameer E Millat Univ, Dept Surg, Islamabad, Pakistan
关键词
SELECTION CRITERIA; EXPANSION;
D O I
10.1016/j.surg.2024.07.039
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Artificial intelligence-based models might improve patient selection for liver transplantation in hepatocellular carcinoma. The objective of the current study was to develop artificial intelligence-based deep learning models and determine the risk of recurrence after living donor liver transplantation for hepatocellular carcinoma. Methods: The study was a single-center retrospective cohort study. Patients who underwent living donor liver transplantation for hepatocellular carcinoma were divided into training and validation cohorts (n 1/4 192). The deep learning models were used to stratify patients in the training cohort into low- and highrisk groups, and 5-year recurrence-free survival was assessed in the validation cohort. Results: The median follow-up period was 59.1 (33.9-72.4) months. The artificial intelligence model (pretransplant factors) had an area under the curve of 0.86 in the training cohort and 0.71 in the validation cohort. The largest tumor diameter and alpha-fetoprotein level had the greatest Shapley Additive exPlanations values for recurrence (>0.4). The 5-year recurrence-free survival rates in the low- and highrisk groups were 92.6% and 45% (P < .001). In the second artificial intelligence model (pretransplant factors & thorn; grade), the area under the curve for the validation cohort was 0.77, with 5-year recurrence-free survival rates of 96% and 30% in the low- and high-risk groups (P < .001). None of the low-risk patients outside the Milan and University of California San Francisco Criteria had recurrence during follow-up. Conclusions: The artificial intelligence-based hepatocellular carcinoma transplant recurrence models might improve patient selection for liver transplantation. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 50 条
  • [41] Validation in an External Cohort of an Explant-Based Recurrence Prognostic Model After Liver Transplantation for Hepatocellular Carcinoma
    Costentin, Charlotte
    TRANSPLANTATION, 2016, 100 : S110 - S111
  • [42] Ischemic-Free Liver Transplantation Reduces the Recurrence of Hepatocellular Carcinoma After Liver Transplantation
    Tang, Yunhua
    Wang, Tielong
    Ju, Weiqiang
    Li, Fangcong
    Zhang, Qi
    Chen, Zhitao
    Gong, Jinlong
    Zhao, Qiang
    Wang, Dongping
    Chen, Maogen
    Guo, Zhiyong
    He, Xiaoshun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation
    Zhang, Xu
    Chen, Chi
    Wang, Yan
    Xu, Jun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (11) : 2272 - 2280
  • [44] The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Yilmaz, Sezai
    Ince, Volkan
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (04) : 1350 - 1355
  • [45] Early Reoperation and Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Elsabbagh, Ahmed
    Girlanda, Raffaele
    Mckesey, Jacqueline
    Kroemer, Alexander
    Hawksworth, Jason
    Matsumoto, Cal
    Fishbein, Thomas
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 76 - 76
  • [46] No impact of donor sex on the recurrence of hepatocellular carcinoma after liver transplantation
    Taura, Kojiro
    Shimamura, Tsuyoshi
    Akamatsu, Nobuhisa
    Umeshita, Koji
    Fujiyoshi, Masato
    Abe, Hiroyasu
    Morita, Satoshi
    Uemoto, Shinji
    Eguchi, Susumu
    Furukawa, Hiroyuki
    Takada, Yasutsugu
    Egawa, Hiroto
    Ohdan, Hideki
    Hatano, Etsuro
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (05) : 570 - 584
  • [47] Effect of cyclosporine on hepatocellular carcinoma recurrence after liver transplantation.
    Vivarelli, M
    Cucchetti, A
    La Barba, G
    Cavallari, A
    Pinna, AD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 368 - 368
  • [48] Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
    Perera, S.
    Magyar, C. T. J.
    Rajendran, L.
    Li, Z.
    Almugbel, F. A.
    Feng, S.
    Choi, W. J.
    Aceituno, L.
    Selzner, N.
    Jaeckel, E.
    Falla-Rad, N.
    Knox, J. J.
    Chen, E. X.
    O'Kane, G. M.
    Sapisochin, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S82 - S83
  • [49] Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma
    Yilmaz, C.
    Karaca, C. A.
    Lakobadze, Z.
    Farajov, R.
    Kilic, K.
    Doganay, L.
    Kilic, M.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (10) : 3571 - 3576
  • [50] Early recurrence of hepatocellular carcinoma after living donor liver transplantation
    Ohkubo, T
    Sugawara, Y
    Imamura, H
    Kaneko, J
    Matsui, Y
    Makuuchi, M
    HEPATO-GASTROENTEROLOGY, 2004, 51 (55) : 237 - 238